Sattva Sukun Lifecare Reports Mixed FY26 Financials: Annual Profit, Q4 Loss

Consolidated Annual Profit: ₹0.21 crore (₹21.17 lakh)
Consolidated Q4 Loss: -₹0.71 crore (-₹70.99 lakh)

Reader Takeaway: Modest annual profit contrasts with Q4 loss; monitor cash flow and rights issue deployment.

What just happened

Sattva Sukun Lifecare Limited, previously known as Mayukh Dealtrade Limited, announced its audited financial results for the quarter and year ending March 31, 2026. The company posted a consolidated net profit of ₹0.21 crore for the full fiscal year, but incurred a net loss of ₹0.71 crore in the fourth quarter.

Why this matters

The results show a divergence in performance, with the company ending the year profitably overall, but facing operational challenges in the final quarter. This suggests potential seasonality or specific Q4-related pressures. The deployment of funds from a recent rights issue into business expansion and subsidiary investment is crucial for future growth.

The backstory

Sattva Sukun Lifecare Limited operates in the healthcare sector. The company had previously raised ₹19.16 crore through a Rights Issue. The results filing details how these funds were allocated and utilized as of March 31, 2026.

What changes now

Investors will be looking for signs of improved operational performance in the upcoming quarters to overcome the Q4 loss. The effective utilization of the rights issue proceeds for business expansion and investment in its subsidiary will be key indicators of management's strategy to drive future profitability and cash generation.

Risks to watch

A significant concern highlighted is the negative operating cash flow for the year. This indicates that the company's core operations are currently consuming cash rather than generating it, which could pose a liquidity challenge if not addressed.

Peer comparison

(No specific peer comparison data available in the filing.)

Context metrics (time-bound)

Net sales for the year were ₹38.13 crore, a decrease from the ₹14.35 crore reported for the quarter ending March 31, 2026.

What to track next

Investors should closely monitor the company's subsequent quarterly results to assess if the Q4 loss was an anomaly or a trend. Tracking improvements in operating cash flow and the tangible impact of investments made with the rights issue funds will be critical.